back to US directory
us clinical guidance

Osteoporosis screening to prevent fractures

A bounded summary of the 2025 USPSTF primary-screening recommendations and evidence limits.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals assessing adults for primary osteoporosis screening
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Keep the screening population, recommendation grade and evidence limits visibly attributed to the USPSTF.

Scope of this summary

Primary screening in adults aged 40 years or older. The USPSTF recommendation does not apply to people with known osteoporosis, a prior fragility fracture, secondary osteoporosis or long-term medication exposure associated with bone loss.
sources for this section:USPSTF 2025

Recommendation by population

  • Women aged 65 years or older: screen to prevent osteoporotic fractures (Grade B).
  • Postmenopausal women younger than 65 years: when at least one risk factor is present, estimate increased fracture risk with a clinical risk tool and screen those at increased risk (Grade B).
  • Men: current evidence is insufficient to assess the balance of benefits and harms (I statement). This is not the same as a recommendation against screening.
sources for this section:USPSTF 2025

Younger postmenopausal women: two-step approach

1

Identify risk factors

Establish whether at least one recognized osteoporosis or fracture-risk factor is present.
2

Estimate risk

Use a validated clinical risk-assessment tool to determine whether risk is increased.
3

Screen when indicated

Use central DXA bone-mineral-density measurement, with or without fracture-risk assessment, in those at increased risk.
sources for this section:USPSTF 2025

Safety: do not infer beyond the evidence statement

  • Do not convert the I statement for men into a prohibition.
  • Do not invent a universal FRAX intervention threshold from this recommendation.
  • Do not assume an evidence-based repeat-screening interval when the source does not establish one.
  • Use separate pathways for prior fragility fracture, secondary osteoporosis and medication-related bone loss.
sources for this section:USPSTF 2025

Applying the recommendation at the point of care

Preserve the recommendation population and grade when documenting the screening decision. Record the risk factors, clinical risk tool and DXA method used, and move prior fragility fracture, secondary osteoporosis or medication-related bone loss into the appropriate condition-specific pathway.
sources for this section:USPSTF 2025

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. U.S. Preventive Services Task ForceOsteoporosis to Prevent Fractures: ScreeningFinal Recommendation Statement 路 Grades B and I 路 published 2025-01-14 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.